Update on funding decision for two new diabetes medicines

PHARMAC

7 December 2020 - PHARMAC would like to thank everyone who has provided feedback to date on a proposal to fund two new medicines for type 2 diabetes mellitus; empagliflozin (with and without metformin) and dulaglutide.

It is likely that the PHARMAC Board will make a decision on a proposal to fund these medicines in January. 

PHARMAC expects to be able to notify their decision in early February.

Read PHARMAC press release

Michael Wonder

Posted by:

Michael Wonder